Peptidylprolyl isomerase A (PPIA) is a key molecule involved in various biological functions and has been implicated in multiple diseases. However, the biological significance of PPIA in pan-cancer ...

Breast cancer (BC) is the most prevalent malignancy among women, and the steadily increasing disease burden has garnered considerable global attention. Post-translational modifications (PTMs) are ...

Researchers at the University of Arizona R. Ken Coit College of Pharmacy have developed a new strategy that helps the immune ...

Currently, half of patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia—two types of cancer that affect blood cells—do not respond adequately to treatment with CAR-T cells. The ...

The first study on deuterium-depleted water (DDW) concluded that a higher D/H ratio inside cells can trigger cell division. This was supported by lab experiments showing that lowering deuterium levels ...

A research team led by Purdue University's W. Andy Tao has discovered a new type of protein modification related to cellular mutation that impairs a crucial enzyme's ability to help drive energy ...

A team led by Cedars-Sinai Health Sciences University investigators has created a faster, cheaper way to determine the genes expressed in cancerous tumors. The AI-based tool, which they describe in ...

Researchers at the University of California San Diego have developed a large-scale screening approach that identifies ...

T-cell therapy has revolutionized the treatment of hematological malignancies, yet achieving comparable efficacy against ...

Neutrophils are known as first responders to threatening infections and feature prominently in the microenvironment of tumors to resist cancer progression. Though neutrophils have been linked to the ...

If the genome is the blueprint of life, epigenetics is the control system that determines when, where, and how genes are expressed. By revealing how chemical modifications to DNA and chromatin shape ...

Outcomes of young-onset colorectal cancer vs late-onset colorectal cancer patients on phase 1 matched and non-matched therapies. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.